Romvimza in Turkey

Romvimza - overview

Romvimza (vimseltinib) is manufactured by Deciphera Pharmaceuticals (an Ono Pharmaceutical company) and indicated for ITP. It is an Oral CSF1R tyrosine kinase inhibitor (30 mg twice weekly) approved by the US FDA in 2025 and may be accessible to patients in Turkey through a Named Patient Program or personal-import pathway.

Access in Turkey

Turkey's TITCK operates a named-patient program; HCPs coordinate with Turkish Pharmacists' Association.

How Reserve Meds coordinates access in Turkey

1. Patient or treating physician submits a request.
2. We verify clinical appropriateness and Turkey-specific eligibility.
3. Treating physician in Turkey issues prescription and clinical justification.
4. Country-specific NPP/personal-import forms are prepared and filed.
5. We source Romvimza from a DSCSA-compliant US specialty wholesaler.
6. Cold-chain shipment to the patient's physician or hospital pharmacy in Turkey.

Typical timeline for Turkey

End-to-end, most requests are completed in 2-6 weeks. Turkey's tier 2 regulatory maturity typically supports moderate processing times.

What patients and physicians in Turkey ask

• Is the pathway legal in Turkey? Yes - it operates under Turkey's established NPP or personal-import framework.
• Does my insurance cover it? Typically no for NPP drugs; patient prepayment is standard.
• What physician credentials do I need? A licensed physician in Turkey able to issue the prescription and clinical justification.
• What if the drug is in shortage? We will inform you upfront and decline rather than promise what we cannot deliver.
• Can I re-supply? Yes - for chronic therapies we arrange ongoing re-supply.

Start a request for Romvimza in Turkey

Join the Romvimza waitlist